Detalhe da pesquisa
1.
Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States.
Blood
; 143(22): 2332-2335, 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635764
2.
Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States.
Am J Hematol
; 98(9): E247-E250, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37401660